S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)

Atrion - ATRI Stock Forecast, Price & News

$574.00
+9.00 (+1.59%)
(As of 10/3/2022 05:11 PM ET)
Add
Compare
Today's Range
$566.73
$580.46
50-Day Range
$545.43
$680.30
52-Week Range
$542.10
$805.62
Volume
6,267 shs
Average Volume
4,016 shs
Market Capitalization
$1.03 billion
P/E Ratio
30.23
Dividend Yield
1.52%
Price Target
N/A

Atrion MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
4.51% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
1.60mentions of Atrion in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

255th out of 1,093 stocks

Surgical & Medical Instruments Industry

30th out of 105 stocks

ATRI stock logo

About Atrion (NASDAQ:ATRI) Stock

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Receive ATRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atrion and its competitors with MarketBeat's FREE daily newsletter.

ATRI Stock News Headlines

Atrion Corporation Announces CFO Succession Plan
Atrion Corp. Raises Dividend by 10%
Atrion Reports Second Quarter 2022 Results
Atrion Reports First Quarter 2022 Results
Atrion declares $1.95 dividend
Atrion: Q4 Earnings Snapshot
Atrion Reports Fourth Quarter and Full Year 2021 Results
Atrion Corporation
See More Headlines
Receive ATRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atrion and its competitors with MarketBeat's FREE daily newsletter.

ATRI Company Calendar

Last Earnings
8/08/2022
Ex-Dividend for 9/30 Dividend
9/14/2022
Dividend Payable
9/30/2022
Today
10/03/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ATRI
CUSIP
04990410
Employees
667
Year Founded
N/A

Profitability

Net Income
$33.06 million
Pretax Margin
22.02%

Debt

Sales & Book Value

Annual Sales
$165.01 million
Cash Flow
$25.91 per share
Book Value
$135.67 per share

Miscellaneous

Free Float
1,381,000
Market Cap
$1.03 billion
Optionable
Not Optionable
Beta
0.26

Key Executives

  • Mr. Emile A. Battat (Age 84)
    Exec. Chairman
    Comp: $666.55k
  • Mr. David A. Battat (Age 52)
    Pres & CEO
    Comp: $1.94M
  • Mr. Jeffery Strickland (Age 63)
    CFO, VP, Treasurer & Sec.
    Comp: $986.38k













ATRI Stock - Frequently Asked Questions

How have ATRI shares performed in 2022?

Atrion's stock was trading at $704.90 on January 1st, 2022. Since then, ATRI shares have decreased by 19.5% and is now trading at $567.54.
View the best growth stocks for 2022 here
.

When is Atrion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ATRI earnings forecast
.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) released its earnings results on Monday, August, 8th. The medical instruments supplier reported $5.20 earnings per share for the quarter. The medical instruments supplier had revenue of $48.88 million for the quarter. Atrion had a trailing twelve-month return on equity of 14.03% and a net margin of 19.12%.

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion declared a quarterly dividend on Monday, August 22nd. Stockholders of record on Thursday, September 15th will be given a dividend of $2.15 per share on Friday, September 30th. This represents a $8.60 annualized dividend and a dividend yield of 1.52%. The ex-dividend date is Wednesday, September 14th. This is an increase from the stock's previous quarterly dividend of $1.95.
Read our dividend analysis for ATRI
.

Is Atrion a good dividend stock?

Atrion (NASDAQ:ATRI) pays an annual dividend of $8.60 per share and currently has a dividend yield of 1.52%. The company has been increasing its dividend for 18 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 45.29%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for ATRI.

What is David A. Batta's approval rating as Atrion's CEO?

1 employees have rated Atrion Chief Executive Officer David A. Batta on Glassdoor.com. David A. Batta has an approval rating of 100% among the company's employees. This puts David A. Batta in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Atrion to a friend.

What other stocks do shareholders of Atrion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atrion investors own include International Paper (IP), AT&T (T), WestRock (WRK), AbbVie (ABBV), Caterpillar (CAT), Eastman Chemical (EMN), Gilead Sciences (GILD), Altria Group (MO), Pfizer (PFE) and Philip Morris International (PM).

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

How do I buy shares of Atrion?

Shares of ATRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $567.54.

How much money does Atrion make?

Atrion (NASDAQ:ATRI) has a market capitalization of $1.01 billion and generates $165.01 million in revenue each year. The medical instruments supplier earns $33.06 million in net income (profit) each year or $18.99 on an earnings per share basis.

How many employees does Atrion have?

The company employs 667 workers across the globe.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The official website for the company is www.atrioncorp.com. The medical instruments supplier can be reached via phone at (972) 390-9800, via email at ir-info@atrioncorp.com, or via fax at 972-396-7581.

This page (NASDAQ:ATRI) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.